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Accelerated (dose-dense) chemotherapy, in which the frequency of administration is increased without changing total dose or
duration, may increase the efficacy of cancer chemotherapy. We performed a randomised Phase II study to assess the safety and
relative toxicity of AC (doxorubicin; cyclophosphamide) vs E(epirubicin)C given by conventional or accelerated schedules as
neoadjuvant or adjuvant chemotherapy for early breast cancer. Furthermore, the relative toxicity of doxorubicin and epirubicin
remains uncertain. Patients were randomised to one of four arms; four courses of standard 3 weekly cyclophosphamide 600mgm
 2
in combination with doxorubicin 60mgm
 2 (AC) vs epirubicin 90mgm
 2 (EC) 3 weekly vs the same regimens administered every 2
weeks with pegfilgrastim (G-CSF). A total of 126 patients were treated, 42 with standard AC, 42 with accelerated AC, 19 with
standard EC and 23 with accelerated EC. Significantly more grade 3/4 day one neutropenia was seen with standard (6/61, 10%)
compared to accelerated (0/65,) regimens (P¼0.01). A trend towards more neutropenic sepsis was seen in the combined standard
and accelerated AC arms (12/84, 14%) compared to the combined EC arms (1/42, 2%), P¼0.06. Falls in left ventricular ejection
fraction were not increased with accelerated treatment. Accelerated AC and EC with pegfilgrastim are safe and feasible regimens in
the treatment of early breast cancer with less neutropenia than conventional 3 weekly schedules.
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Adjuvant anthracycline chemotherapy results in a significant
survival benefit in women with moderate to high-risk early breast
cancer (Early Breast Cancer Trialists’ Collaborative Group, 2005).
A large randomised trial has demonstrated four cycles of adjuvant
doxorubicin and cyclophosphamide (AC) to be as effective as 6
cycles of CMF (cyclophosphamide, methotrexate and 5-FU) in
women with node-positive disease (Fisher et al, 1990). Subse-
quently, AC has become widely used throughout the world.
Adjuvant anthracycline-based schedules have frequently included
epirubicin instead of doxorubicin, but no data exist directly
comparing the efficacy and safety of these two anthracyclines in
early breast cancer.
Taxanes given sequentially or concurrently with anthracyclines
have resulted in a further small, but significant, improvement in
disease-free and overall survival particularly in node-positive
disease (Bria et al, 2006), but short duration anthracycline/
cyclophosphamide schedules are still widely used for moderate
risk patients.
A randomised trial of 2005 women has demonstrated a
significant survival benefit for women, with lymph node-positive
breast cancer, treated with dose-dense (2 weekly) chemotherapy
with granulocyte colony stimulating factor (G-CSF) support
compared to conventional 3 weekly schedules (Citron et al, 2003).
Our study aimed to assess the safety profile including cardiac
safety of short duration (4 courses) standard AC vs EC given
3-weekly compared with accelerated 2-week schedules of these two
regimens.
PATIENTS AND METHODS
Patient selection
Patients with early breast cancer, suitable for adjuvant chemother-
apy, were recruited following Research Ethics Committee approval.
Written informed consent was obtained before trial entry.
Inclusion criteria were age less than 70 years; ECOG performance
status 0–1; adequate haematological, renal and hepatic function;
normal left ventricular ejection fraction (LVEF), assessed using
multigated acquisition (MUGA) scan or echocardiography. Further
inclusion criteria for the adjuvant arms were complete excision of
histological confirmed adenocarcinoma; axillary resection or
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ssentinel node biopsy; lymph node negative disease or 1–3 involved
nodes if postmenopausal. Those entered into the neoadjuvant arms
were required to have palpable tumours X2cm.
Patient assessment
Initial assessment included history and physical examination, full
blood count, routine biochemistry, hormone receptor status, chest
X-ray, electrocardiogram and MUGA scan. For the neoadjuvant
arms, bi-dimensional calliper tumour measurements were ob-
tained before therapy and after each cycle as well as ultrasono-
graphy at baseline and following cycles 2 and 4.
Treatment
Patients were randomly assigned to one of four arms:
Standard AC – four cycles of doxorubicin 60mgm
 2 and
cyclophosphamide 600mgm
 2 on day 1, every 21 days;
Accelerated AC – four cycles of doxorubicin 60mgm
 2 and
cyclophosphamide 600mgm
 2 on day 1, every 14 days with depot
recombinant human G-CSF (pegfilgrastim) 6mg subcutaneous
injection on day 2 (Neulasta; Amgen, Cambridge, UK);
Standard EC – four cycles of epirubicin 90mgm
 2 and
cyclophosphamide 600mgm
 2 on day 1, every 21 days;
Accelerated EC – four cycles of epirubicin 90mgm
 2 and
cyclophosphamide 600mgm
 2 on day 1, every 14 days with
pegfilgrastim on day 2.
Neoadjuvant patients were only randomised into the AC arms,
because epirubicin was not recognised as a standard neoadjuvant
therapy at the time of designing this trial.
Adjuvant endocrine therapy for a minimum of 5 years was given
to those with hormone receptor-positive disease. Adjuvant radio-
therapy was administered according to local policy at standard
dose and fractionation.
Response and toxicity assessment
Clinical response was assessed before each cycle of neoadjuvant
chemotherapy using WHO criteria (Miller et al, 1981). A
pathological complete response (pCR) was defined as complete
disappearance of invasive cancer cells in breast and nodes on
histological examination (Sataloff et al, 1995).
Toxicity for each cycle was recorded before the commencement
of the following cycle and was evaluated using the National Cancer
Institute Common Toxicity Criteria. Haematological toxicity was
determined before each course (day 21 for standard and day 14 for
accelerated regimens).
End points
The primary end point was the incidence of grade 3/4 neutropenia
on day 1 of each cycle. Secondary endpoints were to compare other
toxicity including cardiotoxicity; compliance and feasibility; the
percentage of intended dose given.
Cardiotoxicity
Anthracycline cardiotoxicity was not anticipated with the cumu-
lative doses used, but a protocol specification was included to
identify any patient with cardiac failure and exclude them from
further anthracycline-based therapy. Assessment of LVEF was
performed at baseline, completion of chemotherapy, 1 and 2 years
after chemotherapy.
Dose modifications
Dose modifications were made for main toxicities as follows:
Myelosuppression Chemotherapy was delayed by weekly intervals
(maximum 3 weeks for 3 weekly and 2 weeks for 2 weekly
regimens) until the neutrophil count X1 10
9 per litre and
platelet count X100 10
9 per litre.
Febrile neutropenia For standard arms, the dose of anthracycline
and cyclophosphamide were reduced by 20% and G-CSF
administered according to American Society of Clinical Oncology
guidelines (Ozer et al, 2000). For accelerated arms, 20% dose
reduction of anthracycline and cyclophosphamide was made in
subsequent cycles.
Statistical methods
To answer the trial aims, 82 evaluable patients were required to be
randomised in the adjuvant arms. This component of the study
was designed to have a 90% probability of detecting a 30%
reduction in grade 3/4 neutropenia from 40% (AC/EC) to 10%
(accelerated AC/EC). Randomisation was performed indepen-
dently through the Institute of Cancer Research Clinical Trials
and Statistics Unit.
Patient demographics and tumour characteristics of the
different arms were compared, separately for adjuvant and
neoadjuvant patients, between the randomised groups to check
for any imbalance. The Kruskal–Wallis test was used for
continuous or ordered categorical variables. The w
2-test or Fisher’s
exact test was used for comparison of binary variables.
All comparisons were two sided and, despite multiple testing,
differences are reported at the 0.05 level of significance.
Comparisons were made between all patients treated with AC
regimens and all patients treated with EC regimens. Comparisons
were also made between all patients treated with accelerated
regimens and all patients treated with standard regimens.
RESULTS
A total of 128 patients were randomised, and 126 analysed. Two
(2%) were excluded; one withdrew consent and the other had
bilirubin and transaminase levels X1.5 upper limit of normal. The
number randomised into each arm with their clinical and
pathological characteristics is shown in Table 1. Median follow
up is 23 months. Eight (6%) patients have relapsed and three (2%)
have died. In 18 (14%) patients, 28 serious adverse events were
recorded; 14 patients in the standard and 11 patients in the
accelerated AC arms, and 1 in the standard and 2 patients in the
accelerated EC arms.
Haematological toxicity
The number of patients with grade 3/4 haematological toxicity in
each subgroup (ie standard AC, accelerated AC, standard EC and
accelerated EC) is shown in Table 2.
Significantly worse day 1, grade 3/4 neutropenia was seen in the
standard (6 out of 61, 10%) compared to the accelerated (0 out of
65) arms, P¼0.01. There were seven episodes of neutropenic
sepsis in the standard arms (11%; all AC) and six (9%) in the
accelerated arms (five AC and one EC), P¼0.7.
No significant difference in day 1, grade 3/4 neutropenia was
observed between the combined 2 and 3 weekly AC arms (3 out of
84 patients, 4%) and combined 2 and 3 weekly EC arms (3 out of
42, 7%), P¼0.4. There were 12 (out of 84, 14%) cases of
neutropenic sepsis in the AC compared with only one (out of 42,
2%) in the EC arms, P¼0.06.
No significant difference in day 1 grade 3/4 haematological
toxicity was observed between the standard AC and standard EC
arms (Table 3). Similarly, no significant difference in day 1 grade
3/4 haematological toxicity was observed between the accelerated
AC and accelerated EC arms (Table 3).
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Of 84 patients, 5 (6%) treated with AC received only two courses of
neoadjuvant chemotherapy because of failure to respond.
Three patients were treated with three cycles, one (2%)
on standard neoadjuvant AC discontinued therapy due to consti-
pation and leg pain, and another on accelerated neoadjuvant AC
developed a chest infection following three cycles. A patient on
accelerated EC was treated for cellulitis and received three cycles.
No significant difference in completing the intended course
of chemotherapy was observed between the treatment arms
(AC vs EC, P¼0.6 and standard vs accelerated, P¼1.0). The
remaining 118 women completed four cycles.
Treatment delays and additional growth factor support
Of 84 patients, 5 (6%) treated with AC were delayed for 1 week and
1 (1%) for 2 weeks compared to 4 patients (out of 42, 10%) delayed
for 1 week in the EC arms and 1 (2%) for two weeks, P¼0.5
(Table 2). Of 61 patients, 4 (7%) in the standard arms were delayed
for 1 week and 5 (out of 65, 8%) in the accelerated arms and a
further 2 in the accelerated arms were delayed for 2 weeks, P¼0.5.
Three patients underwent dose reduction, 2 out of 42 (5%) in
the standard AC arm and 1 out of 42 (2%) in the accelerated AC
arm.
Of 84 patients, 13 (16%) in the AC arms required additional
G-CSF compared to 4 (out of 42, 10%) in the EC arms, P¼0.4
(Table 2). Of 61 patients, 13 (21%) in the standard arms required
G-CSF support compared to 4 out of 65 (7%) in the accelerated
arms who required additional G-CSF support, P¼0.02.
Cardiotoxicity
No patient developed clinical cardiac failure. One patient in the
standard AC arm had a fall in LVEF X10% to below 50%, which
subsequently recovered to 53%. No significant difference in LVEF
falls of X10% between the AC and EC arms was observed on
completing treatment (P¼0.9), 1 (P¼0.5) and 2 (P¼1.0) years
Table 1 Clinical characteristics of patients in the four randomised arms
Standard AC Accelerated AC Standard EC Accelerated EC
All Patients N (%) N (%) N (%) N (%)
Patients: 42 42 19 23
Adjuvant 23 (55) 19 (45) 19 (100) 23 (100)
Neoadjuvant 19 (45) 23 (55)
Age: Median (Range) 48 (33–68) 50 (28–67) 50 (35–68) 56 (31–66)
Menopausal status:
Pre 21 (50) 18 (43) 12 (63) 7 (37)
Peri 1 (2) 7 (17) 0 1 (5)
Post 17 (41) 12 (29) 5 (26) 12 (63)
Hysterectomy 3 (7) 5 (12) 2 (11) 3 (16)
Receptor status:
ER/PR (+), HER2 (+) 4 (10) 5 (12) 2 (11) 3 (13)
ER/PR (+), HER2 ( ) 13 (31) 20 (48) 11 (58) 10 (43)
ER (+), PR ( ), HER2 (+) 3 (7) 1 (2) 0 0
ER (+), PR ( ), HER2 ( ) 5 (12) 3 (7) 0 2 (9)
ER ( ), PR (+), HER2 (+) 1 (2) 0 0 1 (4)
ER ( ), PR (+), HER2 ( ) 1 (2) 0 0 0
ER/PR ( ), HER2 (+) 2 (5) 3 (7) 3 (16) 0
ER/PR ( ), HER2 ( ) 11 (26) 10 (24) 2 (11) 7 (30)
N¼2 (5%), ER (þon biopsy/ excision), PR/HER2 ( ) N¼1 (5%), ER/PR ( ), HER2 not known
Pathology (pretreatment):
Infiltrating ductal 36 (86) 36 (86) 16 (84) 19 (83)
Infiltrating lobular 5 (12) 5 (12) 2 (11) 4 (17)
Other 1 (2) 1 (2) 1 (5) 0
Grade:
I 0 2 (5) 1 (5) 1 (4)
II 18 (43) 21 (50) 9 (47) 7 (30)
III 24 (57) 18 (43) 9 (47) 15 (65)
Not known 0 1 (2) 0 0
Vascular invasion:
Positive 6 (14) 5 (12) 4 (21) 2 (9)
Negative 31 (74) 29 (69) 15 (79) 21 (91)
Not known 5 (12) 8 (19) 0 0
Pathology – adjuvant patients only
Pathological size (cm): 1.6 (0.7-5.0) 2.1 (.38-5.4) 1.7 (1.0-6.5) 1.9 (1.2-9.0)
Nodal status:
Positive 3 (13) 6 (32) 2 (11) 6 (26)
Negative 20 (87) 16 (84) 17 (90) 17 (74)
Not done 0 1 (5) 0 0
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X10% between the standard and accelerated arms was observed
on completing treatment (P¼0.7), one (P¼0.8) and two (P¼0.8)
years post therapy.
Other toxicity
Non-haematological toxicity is shown in Table 5.
No significant difference in grade 3/4 stomatitis was observed
between patients treated with both standard regimens, 3 out of 61
(5%), and both accelerated regimens, 4 out of 65 (6%), P¼1.0.
There was a non-significant trend towards more grade 3/4
stomatitis in patients treated with all AC regimens, 7 (out of 84,
8%), compared to all EC regimens, 0 out of 42 (P¼0.09).
No significant difference in grade 3/4 stomatitis was observed
between the standard AC (3/42, 7.1%) and the standard EC (0/19)
arms, P¼0.5. Similarly, no significant difference in grade 3/4
stomatitis was observed between the accelerated AC (4/42, 9.5%)
and accelerated EC (0/23) arms, P¼0.3. No significant difference
in grade 3/4 stomatitis was observed between the standard (3/42,
7.1%) and accelerated (4/42, 9.5%) AC arms (P¼1.0) or between
the standard (0/19) and accelerated (0/23) EC arms.
No significant difference was observed in grade 3/4 infection
rate between those treated with standard, 8 out of 61 (13%), and
accelerated, 8 out of 65 (12%), regimens (P¼1.0). Of 84 patients,
14 (17%) treated with AC developed grade 3/4 infections, including
neutropenic sepsis (see above), compared with 2 (out of 42, 5%)
treated with EC, P¼0.09.
A significant difference in grade 3/4 infection was found
between the standard AC (8/42, 19.0%) and standard EC (0/19)
arms, P¼0.05. No significant difference in grade 3/4 infection rate
was observed between the accelerated AC (6/42, 14.3%) and
accelerated EC (2/23, 8.7%) arms, P¼0.7. Likewise, no significant
difference in grade 3/4 infection rate was seen between the
standard AC (8/42, 19.0%) and accelerated AC (6/42, 14.3%) arms
(P¼0.8) or between the standard EC (0/19) and accelerated EC (2/
23, 8.7%) arms (P¼0.5).
No significant difference in other non-haematological toxicity
was observed between the AC vs EC and standard vs accelerated
arms. There were no reports of grade 3/4 bone pain, and no patient
stopped pegfilgrastim due to bone pain.
Table 2 Grade 3/4 haematological toxicity, treatment delays and additional G-CSF in the four randomised arms
Toxicity
Standard
AC
Accelerated
AC
Standard
EC
Accelerated
EC
Significance
(AC vs EC)
Significance
(standard vs accelerated)
Anaemia
Grade 3 0 3 (7%) 0 0 P¼0.3 P¼0.1
Grade 4 0 1 (2%) 0 0
Leucopenia
Grade 3 1 (2%) 0 1 (5%) 0 P¼1.0 P¼0.2
Grade 4 0 0 0 0
Neutropenia
Grade 3 2 (5%) 0 2 (11%) 0 P¼0.4 P¼0.01
Grade 4 1 (2%) 0 1 (5%) 0
Thromobocytopenia
Grade 3 0 1 (2%) 0 0 P¼1.0 P¼1.0
Grade 4 0 0 0 0
Treatment delays:
1 week 3 (7%) 2 (5%) 1 (5%) 3 (13%) P¼0.5 P¼0.5
2 weeks 0 1 (2%) 0 1 (4%)
Additional GCSF:
10 (24%) 3 (13%) 3 (16%) 1 (4%) P¼0.4 P¼0.02
Table 3 Grade 3/4 haematological toxicity in the standard and
accelerated AC and EC arms
Grade 3/4
leucopenia
Grade 3/4
neutropenia
Grade 3/4
anaemia
Grade 3/4
thrombocytopenia
Standard AC 1 (2.4%) 3 (7.1%) 0 0
Standard EC 1 (5.3%) 3 (15.8%) 0 0
P¼0.5 P¼0.4 P¼1.0 P¼1.0
Accelerated AC 0 0 4 (9.5%) 1 (2.4%)
Accelerated EC 0 0 0 0
P¼1.0 P¼1.0 P¼0.3 P¼1.0
Standard AC 1 (2.4%) 3 (7.1%) 0 0
Accelerated AC 0 0 4 (9.5%) 1 (2.4%)
P¼0.1 P¼0.1 P¼1.0 P¼1.0
Standard EC 1 (5.3%) 3 (15.8%) 0 0
Accelerated EC 0 0 0 0
P¼0.5 P¼0.08 P¼0.1 P¼0.1
Table 4 Decrease in LVEF X10% on completion, 1 and 2 years after
chemotherapy.
LVEF assessment
Standard
AC
Accelerated
AC
Standard
EC
Accelerated
EC
End of therapy 6 (14%) 3 (7%) 2 (11%) 2 (9%)
1 year after therapy 7 (17%) 3 (7%) 0 3 (13%)
2 years after therapy 6 (14%) 3 (7%) 3 (7%) 1 (4%)
Percentage with 2-year
MUGA scans
71% 69% 58% 71%
Comparison k LVEF X10% between AC and EC regimens. End of therapy, P¼0.9.
One year post therapy, P¼0.5. Two years post therapy, P¼1.0. Comparison k LVEF
X10% between standard and accelerated regimens. End of therapy, P¼0.7.
One year post therapy, P¼0.8. Two years post therapy, P¼0.8.
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myelodysplastic syndrome or acute myeloid leukaemia.
Clinical and pathological response rates in the neoadjuvant
arms
No significant difference in clinical complete and partial response
was observed between the standard, 15 (79%), and accelerated AC,
16 (70%), arms (P¼0.6). No significant difference in pCR rate was
observed between the standard, 2 (11%), and accelerated AC, 3
(13%), arms (P¼0.9).
DISCUSSION
This study has demonstrated that accelerated EC and AC given at 2
weekly intervals with pegfilgrastim support are at least as well
tolerated as the same schedules given over standard 3-week
intervals in early breast cancer, with fewer grade 3/4 neutropenia.
Citron et al (2003) compared standard 3 weekly and accelerated 2
weekly schedules of concurrent doxorubicin and cyclophospha-
mide followed by paclitaxel, or sequential doxorubicin, paclitaxel
and cyclophosphamide. As in our study, they found that grade 4
neutropenia was more frequent in the standard 3 weekly schedules
than in the accelerated regimens (33% vs 6%, Po0.0001).
Likewise in a Phase III randomised trial comparing 3 weekly
FEC with the same regimen given every two weeks with G-CSF
support, a higher incidence of leucopenia was observed in the 3
weekly schedule (45 vs 12%, Po0.001; Venturini et al, 2005). In
contrast, a higher incidence of any grade thrombocytopenia
(8 vs 2%) and bone pain (33 vs 4%) was observed in the dose-
dense FEC regimen.
These other trials did not look at cardiotoxicity in detail and it
was therefore reassuring for us to find no evidence of increased
subclinical cardiotoxicity monitored by serial LVEF with the
accelerated vs standard approach in our study.
Our Phase II trial was not powered to detect differences in
efficacy. Citron et al (2003) however showed a significant
improvement in overall survival with dose-dense therapy (risk
ratio¼0.69, P¼0.013), with 3-year overall survival of 92% in the
dose-dense arms and 90% in the 3 weekly arms.
In contrast, no survival difference was found between the
standard and accelerated regimens in the Phase III trial comparing
3 weekly FEC with the same regimen given every 2 weeks with
G-CSF support, with an actuarial 10-year survival of 80% in the
accelerated arm compared with 78% in the standard arm (P¼0.35;
Venturini et al, 2005). However, this trial with 1214 patients had
limited statistical power to answer this question.
This exploratory Phase II trial has shown that EC, with an
epirubicin dose of 90mgm
 2 is at least as well tolerated as AC
using a doxorubicin dose of 60mgm
 2. The trend towards higher
incidence of neutropenic sepsis, grade 3/4 stomatitis and grade 3
nausea/vomiting in the AC arms of our trial suggest that EC may
be a better option and indicate the need for further comparison of
the relative toxicity of doxorubicin and epirubicin. The key issue
here concerns dose. A French adjuvant chemotherapy trial has
shown that epirubicin 100mgm
 2 is more effective than
50mgm
 2 but also more toxic (French Adjuvant Study Group,
2001). The shape of the dose response curve for epirubicin between
50 and 100mgm
 2 and the optimal dose remains a topic of
controversy, but 90mgm
 2 is also widely used and is unlikely to
be significantly less effective than 100mgm
 2. Our observations
reinforce the need for further dose response
data on the efficacy of epirubicin. Interest has also focused on
the use of docetaxel in combination with cyclophosphamide
(Jones et al, 2006).
In conclusion, E(epirubicin dose of 90mgm
 2)C is at least as
well tolerated as A(doxorubicin 60mgm
 2)C and accelerated AC
or EC given 2 weekly with pegfilgrastim support is at least as safe
and as well tolerated as when given conventionally at 3-week
intervals.
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